The biomaterials company QGel has received $12 million to be used to accelerate QGel’s global expansion and broaden the company “organoids” products.
14 Dec 2017
Lausanne, Switzerland

This latest round adds to $8.5 million from previous financing rounds and was led by new private investors.


QGel develops and commercialises synthetic gels for 3D in vitro growth of miniature human organs (organoids) and tumours (tumouroids) that mimic original organs and tumours in certain structure and functions, in a highly scalable way.

3D in vitro disease models

QGel technology gives scientists the ability…

Continue reading…

Back to News and Media